Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX® 25% product to China.
BPL granted licence from the National Medical Products Administration (NMPA) to market ALBUMINEX® 25% product to China
PERMIRA FUNDS TO PARTNER WITH MARCUCCI FAMILY TO INVEST IN KEDRION BIOPHARMA AND BIO PRODUCTS LABORATORY
20 January 2022 – Permira, the global private equity firm, today announces that funds advised by Permira, supported by their co-investor, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), have entered into a partnership with Kedrion’s existing shareholders (the Marcucci family and FSI) to jointly acquire and combine Kedrion and BPL. The combination will create a global player for medicines derived from human blood plasma, which treat patients with rare and life threatening conditions.
BPL to support the Immune Deficiency Foundation Research Grant Program
The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (P.I.), including well-defined research projects with a specified benefit for improving the treatment, health, disease management, or diagnosis of people with P.I. management or diagnosis of people with primary immunodeficiency diseases.
Second Annual Hereditary Factor 10 Deficiency Awareness Day Kicks Off October 10
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, is proud to partner with the National Hemophilia Foundation in recognizing the second Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2021.
BPL Announces the Kick-off of the Hereditary Factor X Deficiency in America Survey
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US offices in Durham, NC announced today, the kick-off of the Hereditary Factor X Deficiency in America Survey, the first of its kind focusing on patients suffering from this ultra-rare bleeding disorder.
BPL 1st Half 2021 Results: BPL delivers a strong performance
Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the six months ending 30 June 2021. BPL is a vertically integrated manufacturer of plasma-derived medicinal products headquartered in Elstree, UK. BPL consists of two divisions, BPL Plasma, based in Texas, which collects plasma from 26 centres across the US, and BPL Therapeutics in the UK, which manufactures high-quality products.
BPL celebrates World Blood Donor Day and the essential contribution of its plasma donors in providing critical therapies worldwide
Bio Products Laboratory (“BPL”), a specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, celebrates World Blood Donor Day (“WBDD”) in recognition of the critical role of donors worldwide in enhancing and saving lives.
Bio Products Laboratory: Support for strong trade links with India
As a growing healthcare market, India is of strategic importance to Bio Products Laboratory (BPL), the specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, as the company continues to grow its global commercial presence there, and represents a business opportunity of up to £70M in the next 5 years.
BPL and Atlantic Research Group enter into long-term collaboration
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies headquartered in Elstree, UK, today announced the signing of a collaboration agreement with Atlantic Research Group (ARG), a global contract research organization (CRO) headquartered in Charlottesville, VA.